Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Sara Bindoli
Early IL‐1 Inhibition in Still's Disease: A Window of Opportunity for Improving Outcomes
INTRODUCTION Still's disease is a multifactorial inflammatory disease first described in children at the end of the 19th century by Sir George Still,1 who termed it “systemic juvenile idiopathic arthritis” (sJIA). In the 1970s, Eric Bywaters observed similar clinical and biologic features in a group of adult women, leading to the adoption of the term “adult-onset Still's disease.”2 Recent studies3, 4 demonstrated that Still's disease is a continuum across ages.
Clinical Images: A rare and misleading condition: isolated skeletal involvement of Erdheim-Chester disease
The patient, a 60-year-old woman with osteoporosis, complained of pain in the right ankle, which spread to the perimalleolar region, and then the left ankle. No fractures were detected on the radiograph; magnetic resonance (MR) imaging showed bone edema in the cuboid–calcaneal bone heads and the left distal metadiaphyseal tibia. The patient received nonsteroidal anti-inflammatory drugs, analgesics, and bisphosphonates for suspected complex regional pain syndrome, without benefit.
EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease
OP A: sJIA and AOSD are the same disease, that should be designated by the same unique name, Still’s disease (formerly called sJIA/AOSD) As mentioned above, AOSD was initially described as the adult counterpart of sJIA and the distinction of the two entities was mainly artificial based on the organisation of paediatric care, with an age limit of 16 years.3 This led in the subsequent decades to the separation of the two entities in terms of definition, classification criteria, clinical trials...
EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease
Discussion This is the first set of recommendations for the diagnosis and management of children and adults with Still’s disease, two entities previously named sJIA and AOSD and distinguished primarily based on an arbitrary cut-off of age at onset. The endorsement by both the adult and the paediatric European rheumatology societies (EULAR and PReS) and the involvement of a large team of paediatric and adult rheumatologists, together with patient’s representatives are major strengths of this work.
Systemic juvenile idiopathic arthritis and adult-onset Still’s disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still’s disease
Discussion To our knowledge, this study is the first SR of comparative cohorts and meta-analysis examining the prevalence of clinical manifestations (including complications) and laboratory findings in sJIA and AOSD. We found a globally similar prevalence of clinical and biological manifestations for sJIA and AOSD, including complications. This is a strong argument supporting a continuum between the two entities.
Efficacy and safety of therapies for Still’s disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still’s disease
Discussion Treatment of sJIA/AOSD has historically been based on NSAIDs and GCs. GCs are effective. However, their use at high or intermediate doses in the medium to long term is associated with severe, well-known side effects. Therefore, physicians are obliged to limit their use. In the past, csDMARDs have been employed to spare GCs. No formal trials with csDMARDs have been performed, except for a randomised crossover design trial with MTX in sJIA.
Proteomic Profiling of Tears in Blau Syndrome Patients in Identification of Potential Disease Biomarkers
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors
Altmetric share Share announcement Help format_quote Cite thumb_up ... Endorse textsms ... Comment Need Help? Support Find support for a specific problem in the support section of our website. Get Support Feedback Please let us know what you think of our products and services. Give Feedback Information Visit our dedicated information section to learn more about MDPI.
IL-18 in Autoinflammatory Diseases: Focus on Adult Onset Still Disease and Macrophages Activation Syndrome
Abstract : Interleukin-18 (IL-18) is a potent pro-inflammatory cytokine that is involved in various innate and adaptive immune processes related to infection, inflammation, and autoimmunity. Therefore, it is described as a key mediator of autoinflammatory diseases associated with the development of macrophage activation syndrome (MAS), including systemic juvenile idiopathic arthritis and adult-onset Still’s disease.
IFN-α induced systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report and literature review
Zhipeng Zeng1 Wei Tu1 Bai Ji2 Jie Liu3 Kecheng Huang4 Daan Nie5* Liu Yang6* 1Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 2Department of Internal Medicine, the People Hospital of Tongshan, Xianning, China 3Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 4Department of Obstetrics and Gynecology, Tongji Hospital, Tongji...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Sara
Contact Sara, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack